DT05 Rec'd PCT/PT0 0 3 DEC 2004

60020830-0003 sequence listing.txt SEQUENCE LISTING

Wun, Tze-Chein <110> <120> Novel Recombinant Anticoagulant Proteins <130> 60020830-0003 <140> PCT/US03/17442 <141> 2003-06-04 <150> us 06/386,932 <151> 2002-06-06 <160> 41 <170> PatentIn version 3.2 <210> <211> 382 <212> PRT Artificial <213> <220> Fusion protein: human-derived ANV with TAP <223> <400> Ala Tyr Asn Arg Leu Cys Ile Lys Pro Arg Asp Trp Ile Asp Glu Cys
10 15 Asp Ser Asn Glu Gly Gly Glu Arg Ala Tyr Phe Arg Asn Gly Lys Gly 20 25 30Gly Cys Asp Ser Phe Trp Ile Cys Pro Glu Asp His Thr Gly Ala Asp Tyr Tyr Ser Ser Tyr Asn Asp Cys Phe Asn Ala Cys Ile Gly Ser Ala 50 60 Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu Arg 65 70 75 80 Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu Leu 115 120 125 Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile Val

Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys His 145 150 155 160

Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile Ile 165 170 175

Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr Glu 180 185 190

Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr Ser 195 200 205

Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg Asp 210 215 220

Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln Ala 225 230 235 240

Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys Phe 245 250 255

Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val Phe 260 265 270

Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile Asp 275 280 285

Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val Lys 290 295 300

Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr Ala 305 310 315 320

Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met Val 325 330 335

Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg Lys 340 345 350

Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser Gly 355 360 365

Asp Tyr Lys Lys Ala Leu Leu Leu Leu Ala Gly Glu Asp Asp 370 380

<210> 2 <211> 378

<212> PRT

<213> Artificial

<220>

<223> Fusion protein: human-derived ANV with artificial 6L15 (a variant of naturally-occurring bovine pancreatic trypsin inhibitor)

<400> 2

Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu 10 15

Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr 20 25 30

Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln
35 40 45

Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu 50 60

Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile 65 70 75 80

Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys 85 90 95

His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile 100 105 110

Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr 115 120 125

Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr 130 135 140

Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg 145 150 155 160

Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln 165 170 175

Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys 180 185 190

Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val

Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile 210 220 Page 3

Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val 225 230 235 240

Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr 245 250 255

Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met 260 265 270

Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg 275 280 285

Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser 290 295 300

Gly Asp Tyr Lys Lys Ala Leu Leu Leu Leu Ala Gly Glu Asp Asp Met 305 310 315 320

His Pro Asp Phe Cys Leu Glu Pro Pro Tyr Asp Gly Pro Cys Arg Ala 325 330 335

Leu His Leu Arg Tyr Phe Tyr Asn Ala Lys Ala Gly Leu Cys Gln Thr 340 350

Phe Tyr Tyr Gly Gly Cys Leu Ala Lys Arg Asn Asn Phe Glu Ser Ala 355 360 365

Glu Asp Cys Met Arg Thr Cys Gly Gly Ala 370 375

<210> <211> 376

<212> PRT

Artificial

Fusion protein:human-derived ANV with synthetic human K-APP

Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu 10 15

Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr $20 \hspace{1cm} 25 \hspace{1cm} 30$

Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln 35 40 45

Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu 50 60

Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile 65 70 75 80

Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys 85 90 95

His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile 100 105 110

Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr 115 120 125

Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr 130 135 140

Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg 145 150 155 160

Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln 165 170 175

Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys 180 185 190

Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val 195 200 205

Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile 210 215 220

Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val Val 225 230 235 240

Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr 245 250 255

Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met 260 265 270

Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg 275 280 285

Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser 290 295 300 Page 5

Gly Asp Tyr Lys Lys Ala Leu Leu Leu Leu Ala Gly Glu Asp Asp Glu 305 310 315 320

Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile Ser 325 330 335

Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe Tyr 340 345 350

Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr Cys 355 360 365

Met Ala Val Cys Gly Ser Ala Ile 370 375

<210> 4

<211> 459

<212> PRT

<213> Artificial

<223> Fusion protein: human-derived ANV with KK-TFPI (a human sequence)

<400> 4

Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu
10 15

Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr 20 25 30

Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln 35 40 45

Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu 50 60

Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile 65 70 75 80

Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys 85 90 95

His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile 100 105 110

Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr 115 120 125

Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr 130 135 140

Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg 145 150 155 160

Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln 165 170 175

Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys 180 185 190

Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val 195 200 205

Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile 210 220

Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val 225 230 235 240

Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr 245 250 255

Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met 260 265 270

Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg 275 280 285

Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser 290 295 300

Gly Asp Tyr Lys Lys Ala Leu Leu Leu Leu Ala Gly Glu Asp Asp Met 305 310 315

His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Lys Ala Ile 325 330 335

Met Lys Arg Phe Phe Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe 340 345 350

Ile Tyr Gly Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu Ser Leu Glu 355 360 365

Glu Cys Lys Lys Met Cys Thr Arg Asp Asn Ala Asn Arg Ile Ile Lys 370 375 380 Page 7

Thr Thr Leu Gln Gln Glu Lys Pro Asp Phe Cys Phe Leu Glu Glu Asp 385 390 395 400

Pro Gly Ile Cys Arg Gly Tyr Ile Thr Arg Tyr Phe Tyr Asn Asn Gln 405 410 415

Thr Lys Gln Cys Glu Arg Phe Lys Tyr Gly Gly Cys Leu Gly Asn Met 420 425 430

Asn Asn Phe Glu Thr Leu Glu Glu Cys Lys Asn Ile Cys Glu Asp Gly 435 440 445

Pro Asn Gly Phe Gln Val Asp Asn Tyr Gly Thr 450 455

<210> 5

<211> 1149 <212> DNA

<213> Artificial

<220>

<223> Fusion gene of human-derived ANV with TAP

<400> 60 gcttacaacc gtctgtgcat caaaccgcgt gactggatcg atgaatgcga ctccaacgaa 120 ggtggtgaac gtgcttactt ccgtaacggt aaaggtggtt gcgactcctt ctggatctgc 180 ccggaagacc acaccggtgc tgactactac tcctcctaca acgactgctt caacgcttgc 240 atcggatccg cacaggttct cagaggcact gtgactgact tccctggatt tgatgagcgg 300 gctgatgcag aaactcttcg gaaggctatg aaaggcttgg gcacagatga ggagagcatc 360 ctgactctgt tgacatcccg aagtaatgct cagcgccagg aaatctctgc agcttttaag 420 actctgtttg gcagggatct tctggatgac ctgaaatcag aactaactgg aaaatttgaa 480 aaattaattg tggctctgat gaaaccctct cggctttatg atgcttatga actgaaacat 540 gccttgaagg gagctggaac aaatgaaaaa gtactgacag aaattattgc ttcaaggaca 600 cctgaagaac tgagagccat caaacaagtt tatgaagaag aatatggctc aagcctggaa 660 gatgacgtgg tgggggacac ttcagggtac taccagcgga tgttggtggt tctccttcag 720 gctaacagag accctgatgc tggaattgat gaagctcaag ttgaacaaga tgctcaggct 780 ttatttcagg ctggagaact taaatggggg acagatgaag aaaagtttat caccatcttt 840 ggaacacgaa gtgtgtctca tttgagaaag gtgtttgaca agtacatgac tatatcagga 900 tttcaaattg aggaaaccat tgaccgcgag acttctggca atttagagca actactcctt 960 gctgttgtga aatctattcg aagtatacct gcctaccttg cagagaccct ctattatgct

60020830-0003 sequence listing.txt atgaagggag ctgggacaga tgatcatacc ctcatcagag tcatggtttc caggagtgag	1020
attgatctgt ttaacatcag gaaggagttt aggaagaatt ttgccacctc tctttattcc	1080
atgattaagg gagatacatc tggggactat aagaaagctc ttctgctgct cgctggagaa	1140
gatgactaa	1149
<210> 6 <211> 1137 <212> DNA <213> Artificial	
<220> <223> Fusion gene of human-derived ANV with artificial 6L15, which variant of naturally occurring bovine pancreatic trypsin inhibitor	is a
<400> 6 gcacaggttc tcagaggcac tgtgactgac ttccctggat ttgatgagcg ggctgatgca	60
gaaactcttc ggaaggctat gaaaggcttg ggcacagatg aggagagcat cctgactctg	120
ttgacatccc gaagtaatgc tcagcgccag gaaatctctg cagcttttaa gactctgttt	180
ggcagggatc ttctggatga cctgaaatca gaactaactg gaaaatttga aaaattaatt	240
gtggctctga tgaaaccctc tcggctttat gatgcttatg aactgaaaca tgccttgaag	300
ggagctggaa caaatgaaaa agtactgaca gaaattattg cttcaaggac acctgaagaa	360
ctgagagcca tcaaacaagt ttatgaagaa gaatatggct caagcctgga agatgacgtg	420
gtgggggaca cttcagggta ctaccagcgg atgttggtgg ttctccttca ggctaacaga	480
gaccctgatg ctggaattga tgaagctcaa gttgaacaag atgctcaggc tttatttcag	540
gctggagaac ttaaatgggg gacagatgaa gaaaagttta tcaccatctt tggaacacga	600
agtgtgtctc atttgagaaa ggtgtttgac aagtacatga ctatatcagg atttcaaatt	660
gaggaaacca ttgaccgcga gacttctggc aatttagagc aactactcct tgctgttgtg	720
aaatctattc gaagtatacc tgcctacctt gcagagaccc tctattatgc tatgaaggga	780
gctgggacag atgatcatac cctcatcaga gtcatggttt ccaggagtga gattgatctg	840
tttaacatca ggaaggagtt taggaagaat tttgccacct ctctttattc catgattaag	900
ggagatacat ctggggacta taagaaagct cttctgctgc tcgctggaga agatgacatg	960
catccggact tctgcctgga accgccgtac gacggtccgt gccgtgctct gcacctgcgt	1020
tacttctaca atgcaaaggc aggcctgtgt cagaccttct actacggcgg ttgcctggct	1080
aagcgtaaca acttcgaatc cgcggaagac tgcatgcgta cttgcggtgg tgcttaa	1137
<210> 7	

<210> / <211> 1131 <212> DNA <213> Artificial

<220> <223> Fusion gene of human-derived ANV with synthetic human K-APP gene	e
<400> 7 gcacaggttc tcagaggcac tgtgactgac ttccctggat ttgatgagcg ggctgatgca	60
gaaactcttc ggaaggctat gaaaggcttg ggcacagatg aggagagcat cctgactctg 1	.20
ttgacatccc gaagtaatgc tcagcgccag gaaatctctg cagcttttaa gactctgttt 1	.80
ggcagggatc ttctggatga cctgaaatca gaactaactg gaaaatttga aaaattaatt 2	40
gtggctctga tgaaaccctc tcggctttat gatgcttatg aactgaaaca tgccttgaag 3	00
ggagctggaa caaatgaaaa agtactgaca gaaattattg cttcaaggac acctgaagaa 3	60
ctgagagcca tcaaacaagt ttatgaagaa gaatatggct caagcctgga agatgacgtg 4	20
gtgggggaca cttcagggta ctaccagcgg atgttggtgg ttctccttca ggctaacaga 4	80
gaccctgatg ctggaattga tgaagctcaa gttgaacaag atgctcaggc tttatttcag 5	40
gctggagaac ttaaatgggg gacagatgaa gaaaagttta tcaccatctt tggaacacga 6	00
agtgtgtctc atttgagaaa ggtgtttgac aagtacatga ctatatcagg atttcaaatt 6	60
gaggaaacca ttgaccgcga gacttctggc aatttagagc aactactcct tgctgttgtg 7	20
aaatctattc gaagtatacc tgcctacctt gcagagaccc tctattatgc tatgaaggga 7	80
gctgggacag atgatcatac cctcatcaga gtcatggttt ccaggagtga gattgatctg 8	40
tttaacatca ggaaggagtt taggaagaat tttgccacct ctctttattc catgattaag 9	00
ggagatacat ctggggacta taagaaagct cttctgctgc tcgctggaga agatgacgag 9	60
gtttgttctg agcaagctga gactggtcca tgtagagcta tgatttctag atggtacttc 10	20
gacgttactg agggtaagtg tgctccattc ttctacggtg gttgtggtgg taacagaaac 10	080
aacttcgaca ctgaggagta ctgtatggct gtttgtggtt ctgctattta a 11	.31
<210> 8 <211> 1380 <212> DNA <213> Artificial <220> <223> Fusion gene of human-derived ANV with KK-TFPI, which is a human sequence	l
<400> 8 gcacaggttc tcagaggcac tgtgactgac ttccctggat ttgatgagcg ggctgatgca	60
	.20
	.20 .80
	240
	100
gtggctctga tgaaaccctc tcggctttat gatgcttatg aactgaaaca tgccttgaag 3 Page 10	JU

ggagctggaa	caaatgaaaa	agtactgaca	gaaattattg	cttcaaggac	acctgaagaa	360
ctgagagcca	tcaaacaagt	ttatgaagaa	gaatatggct	caagcctgga	agatgacgtg	420
gtgggggaca	cttcagggta	ctaccagcgg	atgttggtgg	ttctccttca	ggctaacaga	480
gaccctgatg	ctggaattga	tgaagctcaa	gttgaacaag	atgctcaggc	tttatttcag	540
gctggagaac	ttaaatgggg	gacagatgaa	gaaaagttta	tcaccatctt	tggaacacga	600
agtgtgtctc	atttgagaaa	ggtgtttgac	aagtacatga	ctatatcagg	atttcaaatt	660
gaggaaacca	ttgaccgcga	gacttctggc	aatttagagc	aactactcct	tgctgttgtg	720
aaatctattc	gaagtatacc	tgcctacctt	gcagagaccc	tctattatgc	tatgaaggga	780
gctgggacag	atgatcatac	cctcatcaga	gtcatggttt	ccaggagtga	gattgatctg	840
tttaacatca	ggaaggagtt	taggaagaat	tttgccacct	ctctttattc	catgattaag	900
ggagatacat	ctggggacta	taagaaagct	cttctgctgc	tcgctggaga	agatgacatg	960
cattcatttt	gtgcattcaa	ggcggatgat	ggcccatgta	aagcaatcat	gaaaagattt	1020
ttcttcaata	ttttcactcg	acagtgcgaa	gaatttatat	atgggggatg	tgaaggaaat	1080
cagaatcgat	ttgaaagtct	ggaagagtgc	aaaaaaatgt	gtacaagaga	taatgcaaac	1140
aggattataa	agacaacatt	gcaacaagaa	aagccagatt	tctgcttttt	ggaagaagat	1200
cctggaatat	gtcgaggtta	tattaccagg	tatttttata	acaatcagac	aaaacagtgt	1260
gaacgtttca	agtatggtgg	atcgctgggc	aatatgaaca	attttgagac	actggaagaa	1320
tgcaagaaca	tttgtgaaga	tggtccgaat	ggtttccagg	tggataatta	tggaacctaa	1380
	o sapiens			•		
<400> 9 gcacaggttc	tcagaggcac	tgtgactgac	ttccctggat	ttgatgagcg	ggctgatgca	60
gaaactcttc	ggaaggctat	gaaaggcttg	ggcacagatg	aggagagcat	cctgactctg	120
ttgacatccc	gaagtaatgc	tcagcgccag	gaaatctctg	cagcttttaa	gactctgttt	180
ggcagggatc	ttctggatga	cctgaaatca	gaactaactg	gaaaatttga	aaaattaatt	240
gtggctctga	tgaaaccctc	tcggctttat	gatgcttatg	aactgaaaca	tgccttgaag	300
ggagctggaa	caaatgaaaa	agtactgaca	gaaattattg	cttcaaggac	acctgaagaa	360
ctgagagcca	tcaaacaagt	ttatgaagaa	gaatatggct	caagcctgga	agatgacgtg	420
gtgggggaca	cttcagggta	ctaccagcgg	atgttggtgg	ttctccttca	ggctaacaga	480
gaccctgatg	ctggaattga	tgaagctcaa	gttgaacaag	atgctcaggc	tttatttcag	540
gctggagaac	ttaaatgggg	gacagatgaa	gaaaagttta Page		tggaacacga	600

agtgtgtctc	atttgagaaa	ggtgtttgac	aagtacatga	ctatatcagg	atttcaaatt	660
gaggaaacca	ttgaccgcga	gacttctggc	aatttagagc	aactactcct	tgctgttgtg	720
aaatctattc	gaagtatacc	tgcctacctt	gcagagaccc	tctattatgc	tatgaaggga	780
gctgggacag	atgatcatac	cctcatcaga	gtcatggttt	ccaggagtga	gattgatctg	840
tttaacatca	ggaaggagtt	taggaagaat	tttgccacct	ctctttattc	catgattaag	900
ggagatacat	ctggggacta	taagaaagct	cttctgctgc	tctgtggaga	agatgactaa	960

<210> 10

<211> 319

<212> PR7

<213> Homo sapiens

<400> 10

Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu 10 15

Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr 20 25 30

Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln 35 40 45

Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu 50 60

Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile 65 70 75 80

Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys 85 90 95

His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile 100 105 110

Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr 115 120 125

Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr 130 135 140

Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg 145 150 155 160

Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln
165 170 175
Page 12

Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys
180 185 190

Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val 195 200 205

Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile 210 220

Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val 225 230 235 240

Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr 245 250 255

Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met 260 265 270

Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg 275 280 285

Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser 290 295 300

Gly Asp Tyr Lys Lys Ala Leu Leu Leu Leu Cys Gly Glu Asp Asp 305 310 315

<210>

<211> 33 <212> DNA <213> Artificial

<220>

<223> ANV reverse primer

atcaagctta tgcatgtcat cttctccaca gag

<211> 31 <212> DNA

Artificial

<220>

<223> ANV forward primer

<400>

gatcggatcc agtctggtcc tgcttcacct t

<210> 13

Page 13

33

31

60020830-0003	sequence	listing.txt

32 <212> DNA Artificial <213>

<220>

<211>

Synthetic oligonucleotide used to generate ANV cDNA mutation of <223> Cys-to-Ala at position 315

<400> cgtgacatgc atgtcatctt ctccagcgag ca

32

<210> 14 <211> 960 <212> DNA

<213> Artificial

<220>

Sequence encoding human ANV with Cys-to-Ala mutation at posiiton <223>

<400> 60 gcacaggttc tcagaggcac tgtgactgac ttccctggat ttgatgagcg ggctgatgca qaaactcttc qqaaqqctat qaaaqqcttg ggcacagatg aggagagcat cctgactctg 120 ttgacatccc gaagtaatgc tcagcgccag gaaatctctg cagcttttaa gactctgttt 180 240 qqcaqqqatc ttctqqatqa cctqaaatca qaactaactg gaaaatttga aaaattaatt 300 qtqqctctqa tgaaaccctc tcggctttat gatgcttatg aactgaaaca tgccttgaag 360 qqaqctqqaa caaatqaaaa aqtactqaca gaaattattg cttcaaggac acctgaagaa 420 ctgagagcca tcaaacaagt ttatgaagaa gaatatggct caagcctgga agatgacgtg 480 gtgggggaca cttcagggta ctaccagcgg atgttggtgg ttctccttca ggctaacaga 540 qaccctqatq ctqqaattqa tgaaqctcaa gttgaacaag atgctcaggc tttatttcag 600 gctggagaac ttaaatgggg gacagatgaa gaaaagttta tcaccatctt tggaacacga agtgtgtctc atttgagaaa ggtgtttgac aagtacatga ctatatcagg atttcaaatt 660 720 qaqqaaacca ttgaccgcga gacttctggc aatttagagc aactactcct tgctgttgtg 780 aaatctattc qaaqtatacc tqcctacctt qcaqaqaccc tctattatgc tatgaaggga qctqqqacaq atgatcatac cctcatcaga gtcatggttt ccaggagtga gattgatctg 840 tttaacatca ggaaggagtt taggaagaat tttgccacct ctctttattc catgattaag 900 960 ggagatacat ctggggacta taagaaagct cttctgctgc tcgctggaga agatgactaa

<210> 15 <211> 64

<212> DNA

Artificial <213>

<220>

Synthetic oligonucleotide, first of three forward primers used to <223> generate recombinant 6L15 gene

<400> tccgga	15 cttc tgcctggaac cgccgtacga cggtccgtgc cgtgctctgc acctgcgtta	60
cttc		64
<210> <211> <212> <213>	16 60 DNA Artificial	
<220> <223>	Synthetic oligonucleotide, second of three forward primers used to generate recombinant 6L15	i
<400> tacaate	16 gcaa aggcaggcct gtgtcagacc ttctactacg gcggttgcct ggctaagcgt	60
<210> <211> <212> <213>	17 50 DNA Artificial	
<220> <223>	Synthetic oligonucleotide, third of three forward primers used generate recombinant 6L15 gene	to
<400> aacaact	17 ttcg aatccgcgga acactgcatg cgtacttgcg gtggtgctta	50
<210> <211> <212> <213>	18 63 DNA Artificial	
<220> <223>	Synthetic oligonucleotide, first of three reverse primers used generate recombinant 6L15 gene	to
<400> acgcagg	18 gtgc agagcacggc acggaccgtc gtacggcggt tccaggcaga agtccggatg	60
cat		63
<210> <211> <212> <213>	19 60 DNA Artificial	
<220> <223>	Synthetic oligonucleotide, second of three reverse primers used to generate recombinant 6L15 gene	1
<400> agccag	19 gcaa ccgccgtagt agaaggtctg acacaggcct gcctttgcat tgtagaagta	60
<210> <211>	20 60	

Page 15

60020830-0003 sequence listing.txt <212> DNA Artificial <213> <220> Synthetic oligonucleotide, third of three reverse primers used to <223> generate recombinant 6L15 gene <400> 20 60 agcttaagca ccaccgcaag tacgcatgca gtcttccgcg gattcgaagt tgttacgctt <210> 21 <211> 177 <212> DNA <213> Artificial <220> synthetic 6L15 gene <223> <400> 21 gctccggact tctgcctgga accgccgtac gacggtccgt gccgtgctct gcacctgcgt 60 tacttctaca atgcaaaggc aggcctgtgt cagaccttct actacggcgg ttgcctggct 120 177 aaqcqtaaca acttcqaatc cgcggaagac tgcatgcgta cttgcggtgg tgcttaa <210> .22 <211> 186 <212> DNA Artificial <213> <220> <223> Synthetic, derived from Ornithidoros moubata gene <400> 60 gcttacaacc gtctgtgcat caaaccgcgt gactggatcg acgaatgcga ctccaacgaa ggtggtgaac gtgcttactt ccgtaacggt aaaggtggtt gcgactcctt ctggatctgc 120 180 ccqqaaqacc acaccggtgc tgactactac tcctcctacc gtgactgctt caacgcttgc 186 atctaa <210> 23 122

<211>

<212> DNA Artificial <213>

<220>

Forward synthetic oligonucleotide for generating synthetic K-APP <223> gene with flanking sequences

<400> qqccctaccc cacagatacg gagttgccac cactgaaact tgaggttgtt agagaggttt 60 120 gttctgagca agctgagact ggtccatgta gagctatgat ttctagatgg tacttcgacg 122 tt

<210> 24

60020830-0003 sequence listing.txt <211> 117 <212> DNA Artificial <213> <220> Forward synthetic oligonucleotide for generating synthetic K-APP <223> gene with flanking sequences <400> 60 actgagggta agtgtgctcc attcttctac ggtggttgtg gtggtaacag aaacaacttc gacactgagg agtactgtat ggctgtttgt ggttctgcta tttaaatgca ttgatga 117 <210> 25 <211> 124 <212> DNA Artificial <213> <220> <223> Reverse synthetic oligonucleotide for generating synthetic K-APP gene with flanking sequences <400> 60 ctcagtaacg tcgaagtacc atctagaaat catagctcta catggaccag tctcagcttg 120 ctcagaacaa acctctctaa caacctcaag tttcagtggt ggcaactccg tatctgtggg 124 gtag <210> 26 <211> 115 <212> DNA <213> Artificial <220> Reverse synthetic oligonucleotide for generating synthetic K-APP <223> gene with flanking sequences <400> 60 agcttcatca atgcatttaa atagcagaac cacaaacagc catacagtac tcctcagtgt 115 cqaaqttgtt tctgttacca ccacaaccac cgtagaagaa tggagcacac ttacc <210> 27 <211> 174 <212> DNA Artificial <213>

<220>

Synthetic K-APP gene, derived from human squence <223>

<400> ttcgacgtta ctgagggtaa gtgtgctcca ttcttctacg gtggttgtgg tggtaacaga

gaggtttgtt ctgagcaagc tgagactggt ccatgtagag ctatgatttc tagatggtac 60

174 aacaacttcg acactgagga gtactgtatg gctgtttgtg gttctgctat ttaa

<210> 28

120

<211>	30	60020830-0003 sequence listing.txt	
<212> <213>	DNA Artificial		
<220> <223>	primer		
<400> ggaatte	28 ccat atggcacagg	ttctcagagg	30
<210> <211> <212> <213>	24		
<220> <223>	primer		
	29 catg tcatcttctc	cagc	24
<210> <211> <212> <213>	24		
<220> <223>	primer		
<400> ccaatge	30 catc cggacttctg	cctg	24
<210> <211> <212> <213>	24		
<220> <223>	primer		
<400> ccaatg	31 catt cattttgtgc	attc	24
<210> <211> <212> <213>	32 27 DNA Artificial		
<220> <223>	primer		
<400> acgcgte	32 cgac ttaagcacca	ccgcaag	27
<210> <211> <212>	33 29 DNA		

Page 18

<220> <223>	primer	
<400> acgcgt	33 cgac ttaggttcca taattatcc	29
<210> <211> <212> <213>	34 30 DNA Artificial	
<220> <223>	primer	
<400> ggaatt	34 ccat atggcttaca accgtctgtg	30
<210> <211> <212> <213>		
<220> <223>	primer	
<400> cgggat	35 ccga tgcaagcgtt gaagcag	27
<210> <211> <212> <213>		
<220> <223>	primer	
<400> cgggat	36 ccgc acaggttctc agaggc	26
<210> <211> <212> <213>	37 29 DNA Artificial	
<220> <223>	primer	
<400> acgcgt	37 cgac ttagtcatct tctccagcg	29
<210> <211> <212> <213>	38 31 DNA Artificial	
<220> <223>	Primer designed for generating PCR fragment of interest for	

60020830-0003 sequence listing.txt cloning into vector pPIC9

<400> ccgctcg	38 gaga aaagagcaca ggttctcaga g	31
<210> <211> <212> <213>	39 33 DNA Artificial	
<220> <223>	Primer designed for generating PCR fragment of interest for cloning into yeast expression vector pPIC9	
<400> ataagaa	39 atgc ggccgcttaa atagcagaac cac	33
<210> <211> <212> <213>	40 24 DNA Artificial	
<220> <223>	Primer designed for generating PCR fragment of interest for cloning into yeast expression vector pPIC9	
<400> cgcgata	40 atca tcttctccag cgag	24
<210> <211> <212> <213>	41 20 DNA Artificial	
<220> <223>	Primer designed for generating PCR fragment of interest for cloning into yeast expression vector pPIC9	
<400> gaggtt	41 tgtt ctgagcaagc	20